Focused on advancing genetic medicines for neuromuscular and cardiac diseases Focused on advancing genetic medicines for neuromuscular and cardiac diseases [jsoncontentimporterpro nameoftemplate=”clientapi.gcs-web.com”] Focused on neuromuscular and cardiac rare diseases Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular ... Read more| Solid Biosciences
Dear Duchenne Community, We are pleased to share a meaningful update on the INSPIRE DUCHENNE clinical study, our multi-center, open-label clinical trial evaluating SGT-003, our investigational gene therapy for the treatment of Duchenne muscular dystrophy. As of August 12, 2025, 15 patients living with Duchenne have received SGT-003 in this study. The trial now includes ... Read more| Solid Biosciences
Dear CPVT Community, We are pleased to introduce Solid Biosciences to the CPVT community—and to share important news about our investigational gene therapy, SGT-501. Patient-focused and founded by individuals directly impacted by Duchenne muscular dystrophy, Solid’s mission is to improve the daily lives of people living with rare neuromuscular and cardiac conditions. What began as ... Read more| Solid Biosciences
Dear Friedreich’s Ataxia Community, We are excited to officially introduce Solid Biosciences to the FA community. Solid Biosciences was founded by individuals directly impacted by Duchenne muscular dystrophy, driven by a deeply personal mission to develop meaningful therapies for patients and families. Since that time, our mission has expanded to include other urgent, rare neuromuscular ... Read more| Solid Biosciences
Dear Duchenne Community, Earlier today we reported third quarter financial results and provided updates on Solid Biociences Inc.’ (“Solid”) business. Among the highlights, we shared new information about INSPIRE DUCHENNE, our clinical trial of our next-generation AAV gene therapy candidate, SGT-003, for the treatment of patients living with Duchenne. INSPIRE DUCHENNE: Status update INSPIRE DUCHENNE ... Read more| Solid Biosciences
Dear Duchenne Community, We are writing to share an important update on INSPIRE DUCHENNE, our Phase 1/2 clinical trial of SGT-003 for the treatment of patients living with Duchenne. At Solid Biosciences, our mission is driven by the needs and hopes of the Duchenne community, and we are grateful for the trust and partnership you have ... Read more| Solid Biosciences
Dear Duchenne Community – Since day one, Solid Biosciences has been focused on developing meaningful therapies for patients with Duchenne muscular dystrophy. This cause is deeply embedded in our organization, which was founded by individuals impacted by Duchenne. Today, we are pleased to announce that Solid received clearance by the U.S. Food and Drug Administration ... Read more| Solid Biosciences
Dear Duchenne Community, This morning we issued a press release providing a full-year 2022 business update. Among the highlights, Solid completed the acquisition of AavantiBio, creating a precision genetic medicines company with a focus on cardiac and neuromuscular diseases, including Duchenne. IGNITE DMD Phase I/II Clinical Trial Update On March 19, Solid presented one-year post-treatment data relating ... Read more| Solid Biosciences
Letter to the Duchenne Community:| Solid Biosciences